At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...
NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...
Earlier this week, WuXi sold its vaccine site in Ireland to MSD International, a subsidiary of Merck. The site was initially built for Merck after WuXi secured a 20-year contract in 2019.
Fierce Pharma Asia—A $410M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
China’s WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to US drug maker Merck & Co for about US$500 million, ahead of potential US legislation that would restrict ...
US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation ...
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate ...
Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback